1231929-97-7 | N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine

Packsize	Purity	Availability	Price	Discounted Price
1mg	97%	in stock	$48.00	$34.00
25mg	97%	in stock	$59.00	$41.00
250mg	97%	in stock	$68.00	$48.00
1g	97%	in stock	$153.00	$107.00
5g	97%	in stock	$448.00	$314.00
10g	97%	in stock	$758.00	$531.00
25g	97%	in stock	$1,504.00	$1,053.00

Description

• Catalog Number: AA25910
• Chemical Name: N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine
• CAS Number: 1231929-97-7
• Molecular Formula: C27H32F2N8
• Molecular Weight: 506.5934
• MDL Number: MFCD22665744
• SMILES: CCN1CCN(CC1)Cc1ccc(nc1)Nc1ncc(c(n1)c1cc(F)c2c(c1)n(C(C)C)c(n2)C)F

Computed Properties

• Complexity: 723
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 37
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 7
• XLogP3: 3.8

Literature

• A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.

  Clinical pharmacokinetics 20180101

• Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

  Cancer discovery 20160701

• Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.

  British journal of cancer 20160315

• Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

  Cancer cell 20160314

• Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.

  Discovery medicine 20160101

• Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.

  Drug metabolism and disposition: the biological fate of chemicals 20150901

• A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.

  Cancer biology & therapy 20130701

• The requirement for cyclin D function in tumor maintenance.

  Cancer cell 20121016

• Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

  Cancer cell 20121016

• Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

  Cell cycle (Georgetown, Tex.) 20120715

• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  Cancer cell 20100713

• The landscape of somatic copy-number alteration across human cancers.

  Nature 20100218